Tags: Watson | Actavis

Watson Buys Generic Drugmaker Actavis for $5.6 Billion

Wednesday, 25 April 2012 04:30 PM

Watson Pharmaceuticals Inc. is buying another generic drugmaker, Switzerland's Actavis Group, for about $5.6 billion in a move that will make Watson in the world's third-biggest generic drugmaker.

Watson, which has seen its profits surge since it started selling an authorized generic version of cholesterol blockbuster Lipitor in December, is now No. 4 globally.

Privately held Actavis operates in more than 40 countries and sells more than 1,000 products.

Watson CEO Paul Bisaro said in a statement that the deal will boost its position in other countries and complement its products in the U.S.

Watson is based in Parsippany, N.J.

The companies are expected to have 2010 combined revenue of about $8 billion.

© Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

1Like our page
Wednesday, 25 April 2012 04:30 PM
Newsmax Media, Inc.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved